PH12021550530A1 - Cd200r agonist antibodies and uses thereof - Google Patents
Cd200r agonist antibodies and uses thereofInfo
- Publication number
- PH12021550530A1 PH12021550530A1 PH12021550530A PH12021550530A PH12021550530A1 PH 12021550530 A1 PH12021550530 A1 PH 12021550530A1 PH 12021550530 A PH12021550530 A PH 12021550530A PH 12021550530 A PH12021550530 A PH 12021550530A PH 12021550530 A1 PH12021550530 A1 PH 12021550530A1
- Authority
- PH
- Philippines
- Prior art keywords
- agonist antibodies
- cd200r agonist
- cd200r
- gvhd
- ibd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731204P | 2018-09-14 | 2018-09-14 | |
| PCT/US2019/050511 WO2020055943A1 (en) | 2018-09-14 | 2019-09-11 | Cd200r agonist antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550530A1 true PH12021550530A1 (en) | 2022-02-14 |
Family
ID=68051977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550530A PH12021550530A1 (en) | 2018-09-14 | 2021-03-11 | Cd200r agonist antibodies and uses thereof |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11319370B2 (https=) |
| EP (1) | EP3849667A1 (https=) |
| JP (3) | JP7185051B2 (https=) |
| KR (1) | KR102705378B1 (https=) |
| CN (2) | CN112739422B (https=) |
| AR (1) | AR116668A1 (https=) |
| AU (1) | AU2019339334B2 (https=) |
| BR (1) | BR112021003254A2 (https=) |
| CA (1) | CA3112763C (https=) |
| CL (1) | CL2021000606A1 (https=) |
| CO (1) | CO2021003093A2 (https=) |
| CR (1) | CR20210134A (https=) |
| DO (1) | DOP2021000040A (https=) |
| EA (1) | EA202190530A1 (https=) |
| EC (1) | ECSP21017619A (https=) |
| IL (1) | IL281442B2 (https=) |
| JO (1) | JOP20210048B1 (https=) |
| MA (1) | MA53604A (https=) |
| MX (1) | MX2021003026A (https=) |
| MY (1) | MY196156A (https=) |
| NZ (1) | NZ773626A (https=) |
| PE (1) | PE20211742A1 (https=) |
| PH (1) | PH12021550530A1 (https=) |
| SG (1) | SG11202101697YA (https=) |
| TW (1) | TWI749367B (https=) |
| WO (1) | WO2020055943A1 (https=) |
| ZA (2) | ZA202101246B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| CN116323665A (zh) | 2020-05-29 | 2023-06-23 | 23和我公司 | 抗cd200r1抗体及其使用方法 |
| PE20251170A1 (es) * | 2022-04-06 | 2025-04-23 | Mirobio Ltd | Anticuerpos cd200r disenados por ingenieria y usos de estos |
| CN115458048B (zh) * | 2022-09-16 | 2023-05-26 | 杭州美赛生物医药科技有限公司 | 基于序列编解码的抗体人源化方法 |
| AU2024282979A1 (en) | 2023-06-02 | 2026-01-22 | Aimed Bio Inc. | Anti-cd200r1 antibody and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368535B2 (en) * | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
| DK1482973T3 (da) * | 2002-03-15 | 2009-12-07 | Schering Corp | Fremgangsmåde til modulering af CD200-receptorer |
| HUE028179T2 (en) * | 2006-01-12 | 2016-12-28 | Alexion Pharma Inc | Antibodies to OX-2 / CD200 and their use |
| KR20090094846A (ko) | 2006-12-22 | 2009-09-08 | 쉐링 코포레이션 | Ｃｄ200ｒ에 대한 항체 |
| CA2786692A1 (en) * | 2010-01-11 | 2011-07-14 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| WO2011100538A1 (en) * | 2010-02-11 | 2011-08-18 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-cd200 antibodies |
| WO2015057906A1 (en) | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
-
2019
- 2019-09-10 AR ARP190102571A patent/AR116668A1/es unknown
- 2019-09-10 TW TW108132514A patent/TWI749367B/zh active
- 2019-09-11 WO PCT/US2019/050511 patent/WO2020055943A1/en not_active Ceased
- 2019-09-11 NZ NZ773626A patent/NZ773626A/en not_active IP Right Cessation
- 2019-09-11 PE PE2021000243A patent/PE20211742A1/es unknown
- 2019-09-11 EA EA202190530A patent/EA202190530A1/ru unknown
- 2019-09-11 CA CA3112763A patent/CA3112763C/en active Active
- 2019-09-11 MX MX2021003026A patent/MX2021003026A/es unknown
- 2019-09-11 CR CR20210134A patent/CR20210134A/es unknown
- 2019-09-11 JP JP2021538177A patent/JP7185051B2/ja active Active
- 2019-09-11 AU AU2019339334A patent/AU2019339334B2/en active Active
- 2019-09-11 CN CN201980060272.1A patent/CN112739422B/zh active Active
- 2019-09-11 BR BR112021003254-1A patent/BR112021003254A2/pt unknown
- 2019-09-11 CN CN202410652453.6A patent/CN118530360A/zh not_active Withdrawn
- 2019-09-11 MY MYPI2021001321A patent/MY196156A/en unknown
- 2019-09-11 KR KR1020217007520A patent/KR102705378B1/ko active Active
- 2019-09-11 IL IL281442A patent/IL281442B2/en unknown
- 2019-09-11 US US16/567,256 patent/US11319370B2/en active Active
- 2019-09-11 EP EP19773670.5A patent/EP3849667A1/en active Pending
- 2019-09-11 MA MA053604A patent/MA53604A/fr unknown
- 2019-09-11 SG SG11202101697YA patent/SG11202101697YA/en unknown
-
2021
- 2021-02-24 ZA ZA2021/01246A patent/ZA202101246B/en unknown
- 2021-03-02 DO DO2021000040A patent/DOP2021000040A/es unknown
- 2021-03-09 CO CONC2021/0003093A patent/CO2021003093A2/es unknown
- 2021-03-11 CL CL2021000606A patent/CL2021000606A1/es unknown
- 2021-03-11 PH PH12021550530A patent/PH12021550530A1/en unknown
- 2021-03-11 JO JOJO/P/2021/0048A patent/JOP20210048B1/ar active
- 2021-03-12 EC ECSENADI202117619A patent/ECSP21017619A/es unknown
-
2022
- 2022-04-21 US US17/726,262 patent/US20220251198A1/en not_active Abandoned
- 2022-05-06 ZA ZA2022/04978A patent/ZA202204978B/en unknown
- 2022-07-28 JP JP2022120801A patent/JP7490025B2/ja active Active
-
2024
- 2024-05-14 JP JP2024078485A patent/JP2024105529A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550530A1 (en) | Cd200r agonist antibodies and uses thereof | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| PH12019502283A1 (en) | Anti-lag3 antibodies | |
| NZ790629A (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| MY202336A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
| MY198562A (en) | Antibodies specifically binding pd-1 and their uses | |
| GEP20207162B (en) | Lag-3-binding molecules and methods of use thereof | |
| MX2019007121A (es) | Anticuerpos anti-ox40 y sus usos. | |
| MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
| SG10201901057UA (en) | Anti-pd-l1 antibodies | |
| PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG10201909716RA (en) | Modified j-chain | |
| PH12022551228A1 (en) | Trem2 antibodies and uses thereof | |
| MX2020012816A (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. | |
| MX2017009803A (es) | Anticuerpos anti-transtiretina. | |
| MY193674A (en) | Anti-transthyretin antibodies | |
| ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
| MX2016008808A (es) | Miembro formado en caliente y proceso para fabricar el mismo. | |
| TN2018000289A1 (en) | Antibodies for il-17c | |
| PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
| ZA201807816B (en) | Anti-il-22r antibodies | |
| PH12017501872A1 (en) | Methods of treating diseases | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| MX378112B (es) | Anticuerpos que potencian el factor h y sus usos. | |
| MX2018009218A (es) | Anticuerpos de cgrp y sus usos. |